ClinicalTrials.gg
CompletedNCT01904058CLARITYUpdated Mar 27, 2019Results posted

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

A Phase 2 interventional study of LUM001 and Placebo in PBC and Primary Biliary Cirrhosis, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 24 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-27.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
26th of 65
66 · median 46
Started
2013
with 1 other
Phase 2
34 of 83
2 open now
Registered
22nd of 83
by date
Lead sponsor
3 of 83
Mirum Pharmaceuticals, Inc.

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 26th largest by enrollment of the 65 interventional ones that give a count, is one of 2 that started in 2013, is one of 34 in phase 2, and was the 22nd registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

The study is a randomized, double-blind, placebo-controlled, multicenter study. It is a 13-week Phase 2 study in adults with primary biliary cirrhosis designed to compare the effect of daily dosing with UDCA in combination with LUM001 or placebo.

03

Conditions studied

  • PBC
  • Primary Biliary Cirrhosis

Keywords

  • PBC
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Primary Biliary Cirrhosis
  2. Moderate to severe pruritus
  3. Taking ursodeoxycholic acid (UDCA) for at least 6 months, or unable to tolerate UDCA
  4. Ability to understand and willingness to sign prior to initiation of any study procedures

Exclusion criteria

Exclusion Criteria:

  1. History or presence of other concomitant significant liver disease
  2. Liver transplant
  3. Known infection
  4. Women who are pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    LUM001 and Ursodeoxycholic Acid (UDCA)

    Administered orally once daily

    Drug: LUM001 · Drug: Ursodeoxycholic Acid

  • Placebo comparator
    Placebo and Ursodeoxycholic Acid (UDCA)

    Administered orally once daily

    Drug: Placebo · Drug: Ursodeoxycholic Acid

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pruritus Using Adult Itch Reported Outcome (ItchRO) Weekly Sum Score at Week 13/ Early Termination (ET)

    Pruritus was assessed using ItchRO measure, administered as an electronic diary (eDiary) which was completed by the participants twice daily (morning and evening). (ItchRO) scores ranged from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. The weekly sum score was calculated as the sum of the daily scores for the 7 days prior to the time point being reported: 7 days prior to randomization or 7 days prior to Week 13/ET visit.

    Time frame: Baseline and Week 13/ET

Secondary outcomes

  1. Change From Baseline in Pruritus Using Adult ItchRO Weekly Sum Scores at Weeks 4, 8 and 13

    ItchRO scores had a range from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. The weekly sum score was calculated as the sum of the daily scores for the 7 days prior to the time point being reported: 7 days prior to randomization or 7 days prior to Week 13/ET visit.

    Time frame: Baseline, Weeks 4, 8 and 13

  2. Change From Baseline in Pruritus Using Adult ItchRO Average Daily Scores at Weeks 4, 8, 13, and Last Post-baseline Visit (Week 13/ET)

    ItchRO scores had a range from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. Adult ItchRO average daily score was the sum of daily scores divided by the number of days adult ItchRO was completed, using the 7 days prior to the reported visit date.

    Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline visit (Week 13/ET)

  3. Change From Baseline in Alkaline Phosphatase (ALP) at Weeks 4, 8, 13, and Last Post-baseline Visit (Week 13/ET)

    Laboratory serum ALP enzyme levels were evaluated using blood samples collected.

    Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline (Week 13/ET)

  4. Change From Baseline in 5-D Itch Score at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)

    The 5-D itch (validated instrument to measure pruritus) scale was developed for the multidimensional quantification of pruritus that is sensitive to change over time. The 5-D itch scale included 5 domains (duration, degree, direction, disability, and distribution of pruritus). The total 5-D score was obtained by scoring each of the domains separately and then summing them together. 5-D total scores ranged between 5 (no pruritus) and 25 (most severe pruritus).

    Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline visit (Week 13/ET)

  5. Change From Baseline in Fasting Serum Bile Acid Level at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)

    Laboratory serum bile acid level levels were evaluated using blood samples collected.

    Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline visit (Week 13/ET)

  6. Change From Baseline in Bile Acid Synthesis as Measured by Serum 7 Alpha-Hydroxy-4-Cholesten-3-One C4 Level [7 Alpha C4]) at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)

    C4 7 alpha-hydroxy-4-cholesten-3-one is an intermediate in the biochemical synthesis of bile acids from cholesterol and its concentrations reflect the activity of the bile acid synthetic pathway. Elevated levels of C4 indicate bile acid malabsorption. Laboratory C4 levels were evaluated using blood samples collected.

    Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline Visit (Week 13/ET)

Other outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. A serious adverse event (SAE) was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly or birth defect; an important medical event that did not meet any of the above criteria but jeopardized the participant or required medical or surgical intervention to prevent one of the outcomes listed above. A TEAE was defined as any AE that occurred during the study, from the start of investigational product dosing through the end of the study (13 weeks of treatment period (or ET) + 14 days \]), or that worsened since the start of dosing.

    Time frame: From the first dose of study drug until the 13 weeks of treatment period (or ET) + 14 days (approximately 15 weeks)

07

Results

Posted Jul 6, 2016

Participant flow

The study was conducted in 24 centers in the United Kingdom, Canada, and the United States between 19 August 2013 and 09 April 2015.

Participant flow — Overall Study
MilestoneLUM001 10 mg + UDCA (Cohort A)LUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B)
Started21211113
Completed18211012
Not completed3011
Withdrew: Adverse event2000
Withdrew: Withdrawal by subject1010
Withdrew: Pregnancy0001

Outcome measures

PrimaryChange From Baseline in Pruritus Using Adult Itch Reported Outcome (ItchRO) Weekly Sum Score at Week 13/ Early Termination (ET)

Pruritus was assessed using ItchRO measure, administered as an electronic diary (eDiary) which was completed by the participants twice daily (morning and evening). (ItchRO) scores ranged from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. The weekly sum score was calculated as the sum of the daily scores for the 7 days prior to the time point being reported: 7 days prior to randomization or 7 days prior to Week 13/ET visit.

Time frame:
Baseline and Week 13/ET
Reported as:
Mean · units on a scale
Change From Baseline in Pruritus Using Adult Itch Reported Outcome (ItchRO) Weekly Sum Score at Week 13/ Early Termination (ET)
units on a scaleLUM001 10 mg + UDCA (Cohort ALUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B)
Baseline48.11 ± 13.36352.10 ± 13.78054.64 ± 9.15749.46 ± 14.110
Change at Week 13/ET-24.59 ± 15.240-27.67 ± 19.888-26.18 ± 18.313-22.77 ± 17.123
Statistical analysis
  • LUM001 10 mg + UDCA (Cohort A vs Placebo + UDCA (Cohort A) vs Placebo + UDCA (Cohort B) · ANCOVA · p = 0.6603 (p-value (LUM001 LS Mean = Placebo LS Mean).) · Least squares mean difference: -2.28 · 95% CI -12.59 to 8.03
  • LUM001 20 mg + UDCA (Cohort B) vs Placebo + UDCA (Cohort A) vs Placebo + UDCA (Cohort B) · ANCOVA · p = 0.4380 (p-value (LUM001 LS Mean = Placebo LS Mean).) · Least squares mean difference: -3.99 · 95% CI -14.20 to 6.23
SecondaryChange From Baseline in Pruritus Using Adult ItchRO Weekly Sum Scores at Weeks 4, 8 and 13

ItchRO scores had a range from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. The weekly sum score was calculated as the sum of the daily scores for the 7 days prior to the time point being reported: 7 days prior to randomization or 7 days prior to Week 13/ET visit.

Time frame:
Baseline, Weeks 4, 8 and 13
Reported as:
Mean · units on a scale
Change From Baseline in Pruritus Using Adult ItchRO Weekly Sum Scores at Weeks 4, 8 and 13
units on a scaleLUM001 10 mg + UDCA (Cohort A)LUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B)
Baseline (n=21, 21, 11, 13)48.11 ± 13.36352.10 ± 13.78054.64 ± 9.15749.46 ± 14.110
Change at Week 4 (n=20, 21, 11, 13)-15.62 ± 13.708-22.19 ± 18.101-10.55 ± 11.103-16.23 ± 12.749
Change at Week 8 (n=20, 21, 10, 13)-21.92 ± 13.089-23.97 ± 20.398-23.50 ± 18.585-19.15 ± 15.302
Change at Week 13 (n=18, 21, 10, 12)-27.41 ± 14.346-27.67 ± 19.888-28.50 ± 17.520-22.92 ± 17.876
SecondaryChange From Baseline in Pruritus Using Adult ItchRO Average Daily Scores at Weeks 4, 8, 13, and Last Post-baseline Visit (Week 13/ET)

ItchRO scores had a range from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. Adult ItchRO average daily score was the sum of daily scores divided by the number of days adult ItchRO was completed, using the 7 days prior to the reported visit date.

Time frame:
Baseline, Weeks 4, 8, 13 and Last Post-baseline visit (Week 13/ET)
Reported as:
Mean · units on a scale
Change From Baseline in Pruritus Using Adult ItchRO Average Daily Scores at Weeks 4, 8, 13, and Last Post-baseline Visit (Week 13/ET)
units on a scaleLUM001 10 mg + UDCA (Cohort A)LUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B)
Baseline (n=21, 21, 11, 13)6.873 ± 1.90917.442 ± 1.96867.805 ± 1.30827.066 ± 2.0158
Change at Week 4 (n=20, 21, 11, 13-2.231 ± 1.9587-3.170 ± 2.5859-1.506 ± 1.5861-2.319 ± 1.8212
Change at Week 8 (n=20, 21, 10, 13)-3.131 ± 1.8703-3.424 ± 2.9139-3.357 ± 2.6549-2.736 ± 2.1860
Change at Week 13 (n=18, 21, 10, 12)-3.915 ± 2.0496-3.952 ± 2.8411-4.071 ± 2.5028-3.274 ± 2.5537
Change at Week 13/ET (n=21, 21, 11, 13)-3.512 ± 2.1774-3.952 ± 2.8411-3.740 ± 2.6161-3.253 ± 2.4461
SecondaryChange From Baseline in Alkaline Phosphatase (ALP) at Weeks 4, 8, 13, and Last Post-baseline Visit (Week 13/ET)

Laboratory serum ALP enzyme levels were evaluated using blood samples collected.

Time frame:
Baseline, Weeks 4, 8, 13 and Last Post-baseline (Week 13/ET)
Reported as:
Mean · units per liter (U/L)
Change From Baseline in Alkaline Phosphatase (ALP) at Weeks 4, 8, 13, and Last Post-baseline Visit (Week 13/ET)
units per liter (U/L)LUM001 10 mg + UDCA (Cohort A)LUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B)
Baseline (n=21, 21, 11, 13)288.2 ± 193.91257.6 ± 190.38253.9 ± 96.83274.2 ± 190.85
Change at Week 4 (n=20, 21, 10, 13)-22.1 ± 54.9413.2 ± 47.7620.3 ± 49.68-0.7 ± 39.69
Change at Week 8 (n=20, 21, 10, 122.6 ± 53.951.1 ± 41.988.8 ± 38.72-4.8 ± 55.70
Change at Week 13 (n=17, 20, 10, 12)-15.2 ± 97.1918.5 ± 56.2124.3 ± 76.48-7.2 ± 83.70
Change at Week 13/ET (n=21, 21, 11, 13)-8.0 ± 93.0216.4 ± 55.6022.9 ± 72.70-7.9 ± 80.19
SecondaryChange From Baseline in 5-D Itch Score at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)

The 5-D itch (validated instrument to measure pruritus) scale was developed for the multidimensional quantification of pruritus that is sensitive to change over time. The 5-D itch scale included 5 domains (duration, degree, direction, disability, and distribution of pruritus). The total 5-D score was obtained by scoring each of the domains separately and then summing them together. 5-D total scores ranged between 5 (no pruritus) and 25 (most severe pruritus).

Time frame:
Baseline, Weeks 4, 8, 13 and Last Post-baseline visit (Week 13/ET)
Reported as:
Mean · units on a scale
Change From Baseline in 5-D Itch Score at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)
units on a scaleLUM001 10 mg + UDCA (Cohort A)LUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B
Baseline (n=21, 21, 11, 13)18.7 ± 3.4719.4 ± 3.4919.6 ± 2.9419.2 ± 3.32
Change at Week 4 (n=20, 21, 10, 13)-4.8 ± 3.91-6.3 ± 4.96-3.4 ± 3.89-4.2 ± 3.81
Change at Week 8 (n=20, 21, 10, 12)-6.8 ± 3.16-5.9 ± 5.62-6.4 ± 6.20-4.4 ± 4.27
Change at Week 13 (n=18, 21, 10, 12)-7.4 ± 3.68-7.0 ± 5.89-7.8 ± 5.94-6.1 ± 4.68
Change at Week 13/ET (n=21, 21, 10, 13)-6.5 ± 4.11-7.0 ± 5.89-7.8 ± 5.94-5.6 ± 4.79
SecondaryChange From Baseline in Fasting Serum Bile Acid Level at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)

Laboratory serum bile acid level levels were evaluated using blood samples collected.

Time frame:
Baseline, Weeks 4, 8, 13 and Last Post-baseline visit (Week 13/ET)
Reported as:
Mean · micromoles per liter
Change From Baseline in Fasting Serum Bile Acid Level at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)
micromoles per literLUM001 10 mg + UDCA (Cohort A)LUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B)
Baseline (n=21, 21, 11, 13)33.110 ± 30.594352.460 ± 94.389252.615 ± 64.616258.434 ± 73.9895
Change at Week 4 (n=20, 21, 10, 13)-11.204 ± 31.6132-14.465 ± 58.5891-10.221 ± 50.039814.317 ± 75.1092
Change at Week 8 (n=20, 21, 10, 12)-3.968 ± 45.7388-21.983 ± 78.6134-3.585 ± 52.439834.893 ± 67.7189
Change at Week 13 (n=18, 21, 10, 12)-8.122 ± 48.1290-19.098 ± 81.845211.481 ± 44.04654.123 ± 46.2170
Change at Week 13/ET (n=21, 21, 10, 13)-4.504 ± 45.7595-19.098 ± 81.845211.481 ± 44.04653.690 ± 44.2770
SecondaryChange From Baseline in Bile Acid Synthesis as Measured by Serum 7 Alpha-Hydroxy-4-Cholesten-3-One C4 Level [7 Alpha C4]) at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)

C4 7 alpha-hydroxy-4-cholesten-3-one is an intermediate in the biochemical synthesis of bile acids from cholesterol and its concentrations reflect the activity of the bile acid synthetic pathway. Elevated levels of C4 indicate bile acid malabsorption. Laboratory C4 levels were evaluated using blood samples collected.

Time frame:
Baseline, Weeks 4, 8, 13 and Last Post-baseline Visit (Week 13/ET)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Change From Baseline in Bile Acid Synthesis as Measured by Serum 7 Alpha-Hydroxy-4-Cholesten-3-One C4 Level [7 Alpha C4]) at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)
nanogram per milliliter (ng/mL)LUM001 10 mg + UDCA (Cohort A)LUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B)
Baseline (n=21, 21, 10, 13)18.74 ± 16.18013.17 ± 11.85122.31 ± 20.76916.98 ± 33.093
Change at Week 4 (n=20, 21, 9, 13)8.66 ± 23.42217.03 ± 18.380-6.80 ± 6.783-0.19 ± 8.856
Change at Week 8 (n=20, 21, 9, 12)13.04 ± 17.89515.03 ± 31.120-12.57 ± 14.6303.43 ± 16.666
Change at Week 13 (n=18, 21, 9, 12)24.38 ± 38.1056.62 ± 10.116-12.72 ± 10.3744.56 ± 13.610
Change at Week 13/ET (n=21, 21, 9, 13)20.56 ± 37.3126.62 ± 10.116-12.72 ± 10.3744.74 ± 13.047
Other pre-specifiedNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. A serious adverse event (SAE) was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly or birth defect; an important medical event that did not meet any of the above criteria but jeopardized the participant or required medical or surgical intervention to prevent one of the outcomes listed above. A TEAE was defined as any AE that occurred during the study, from the start of investigational product dosing through the end of the study (13 weeks of treatment period (or ET) + 14 days \]), or that worsened since the start of dosing.

Time frame:
From the first dose of study drug until the 13 weeks of treatment period (or ET) + 14 days (approximately 15 weeks)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
participantsLUM001 5 mg + UDCALUM001 10 mg + UDCALUM001 20 mg + UDCAPlacebo + UDCA
TEAEs1192117
TESAEs0210

Adverse events

Collected over From the first dose of study drug until the 13 weeks of treatment period (or ET) + 14 days (approximately 15 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LUM001 5 mg + UDCA—0/1 (0%)1/1 (100%)
LUM001 10 mg + UDCA—2/20 (10%)18/20 (90%)
LUM001 20 mg + UDCA—1/21 (4.8%)20/21 (95.2%)
Placebo + UDCA—0/24 (0%)16/24 (66.7%)
Most frequent serious events
Most frequent serious events
EventLUM001 5 mg + UDCALUM001 10 mg + UDCALUM001 20 mg + UDCAPlacebo + UDCA
Myocardial InfarctionCardiac disorders0/11/200/210/24
Abdominal PainGastrointestinal disorders0/11/200/210/24
Gastrointestinal HaemorrhageGastrointestinal disorders0/10/201/210/24
Most frequent other events
Showing 10 of 47
Most frequent other events
EventLUM001 5 mg + UDCALUM001 10 mg + UDCALUM001 20 mg + UDCAPlacebo + UDCA
Abdominal PainGastrointestinal disorders1/14/205/211/24
DiarrhoeaGastrointestinal disorders1/114/2011/216/24
NauseaGastrointestinal disorders1/15/204/214/24
DizzinessNervous system disorders1/10/201/211/24
VomitingGastrointestinal disorders1/10/201/212/24
HeadacheNervous system disorders0/13/202/218/24
Abdominal Pain UpperGastrointestinal disorders0/14/206/212/24
CoughRespiratory, thoracic and mediastinal disorders0/14/201/210/24
Abdominal DistensionGastrointestinal disorders0/13/200/213/24
Pain In ExtremityMusculoskeletal and connective tissue disorders0/10/203/210/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)LUM001 10 mg + UDCA (Cohort A)LUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B)Total
Mean54.7 ± 12.7453.5 ± 10.5347.5 ± 8.1455.8 ± 8.7353.3 ± 10.77
Sex: Female, Male
Sex: Female, Male(Participants)LUM001 10 mg + UDCA (Cohort A)LUM001 20 mg + UDCA (Cohort B)Placebo + UDCA (Cohort A)Placebo + UDCA (Cohort B)Total
Female2017111260
Male14016
08

Study locations

24 sites
  • Scripps Clinic
    La Jolla, California 92037, United States
  • University of California at Davis
    Sacramento, California 95817, United States
  • University of Miami
    Miami, Florida 33136, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Minnesota Gastroenterology
    Saint Paul, Minnesota 55114, United States
  • St. Louis University
    Saint Louis, Missouri 63104, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Advanced Liver Therapies at St. Lukes Episcopal Hospital
    Houston, Texas 77030, United States
  • University of Utah Health Science Center
    Salt Lake City, Utah 84132, United States
  • Liver Institute of Virginia
    Newport News, Virginia 23602, United States
  • Hunter Holmes McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • University of Washington Harborview Medical Center
    Seattle, Washington 98104, United States
  • University Health Network, Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • University of Birmingham
    Birmingham, England B15 2TT, United Kingdom
  • Royal Liverpool & Broadgreen University Hospital
    Liverpool, England L7 8XP, United Kingdom
  • Newcastle University
    Newcastle Upon Tyne, England NE1 4LP, United Kingdom
  • Oxford University Hospitals (John Radcliffe)
    Oxford, England OX3 9DU, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Imperial College London St Mary's Hospital
    London, W2 1NY, United Kingdom
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2013
First posted
Jul 22, 2013
Start
Aug 2013
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Jul 6, 2016
Last update
Mar 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01904058
Responsible party
Sponsor
First posted
Jul 22, 2013
Start date
Aug 2013
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Jul 6, 2016
Last update
Mar 27, 2019

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion